These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 14561945)

  • 1. Psychotropic drug-induced weight gain alleviated with orlistat: a case series.
    Schwartz TL; Beale M
    Psychopharmacol Bull; 2003; 37(1):5-9. PubMed ID: 14561945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatric medication-induced obesity: a review.
    Schwartz TL; Nihalani N; Jindal S; Virk S; Jones N
    Obes Rev; 2004 May; 5(2):115-21. PubMed ID: 15086865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orlistat in the treatment of psychopharmacologically induced weight gain.
    Anghelescu I; Klawe C; Benkert O
    J Clin Psychopharmacol; 2000 Dec; 20(6):716-7. PubMed ID: 11106155
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy.
    Hilger E; Quiner S; Ginzel I; Walter H; Saria L; Barnas C
    J Clin Psychopharmacol; 2002 Feb; 22(1):68-70. PubMed ID: 11799345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpharmacologic and pharmacologic management of weight gain.
    Greenberg I; Chan S; Blackburn GL
    J Clin Psychiatry; 1999; 60 Suppl 21():31-6. PubMed ID: 10548140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case series describing orlistat use in patients on psychotropic medications.
    Carpenter LL; Schecter JM; Sinischalchi J; Leon Z; Price LH
    Med Health R I; 2004 Dec; 87(12):375-7. PubMed ID: 15679228
    [No Abstract]   [Full Text] [Related]  

  • 8. Weight considerations in psychotropic drug prescribing and switching.
    Hasnain M; Vieweg WV
    Postgrad Med; 2013 Sep; 125(5):117-29. PubMed ID: 24113670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of add-on topiramate therapy in psychiatric patients with weight gain.
    Cates ME; Feldman JM; Boggs AA; Woolley TW; Whaley NP
    Ann Pharmacother; 2008 Apr; 42(4):505-10. PubMed ID: 18364406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy for psychotropic drug-related weight gain.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Jul; 46(7):15-8. PubMed ID: 18686592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat: a second look. At best, a minor adjunct to dietary measures.
    Prescrire Int; 2002 Feb; 11(57):10-2. PubMed ID: 11985367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychotropic drug considerations in depressed patients with metabolic disturbances.
    Vieweg WV; Levy JR; Fredrickson SK; Chipkin SR; Beatty-Brooks M; Fernandez A; Hasnain M; Pandurangi AK
    Am J Med; 2008 Aug; 121(8):647-55. PubMed ID: 18691474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat half the dose without a prescription: new status. In excess body weight: often uncomfortable and don't expect miracles. Frequent gastrointestinal disturbances for a weight loss of a few kilos. Better to encourage dietary measures, exercise and individualised support.
    Prescrire Int; 2009 Jun; 18(101):101. PubMed ID: 19637413
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term topiramate treatment of psychotropic drug-induced weight gain: a retrospective chart review.
    Khazaal Y; Chatton A; Rusca M; Preisig M; Zullino D
    Gen Hosp Psychiatry; 2007; 29(5):446-9. PubMed ID: 17888813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
    McElroy SL; Frye MA; Altshuler LL; Suppes T; Hellemann G; Black D; Mintz J; Kupka R; Nolen W; Leverich GS; Denicoff KD; Post RM; Keck PE
    Bipolar Disord; 2007 Jun; 9(4):426-34. PubMed ID: 17547588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of orlistat versus diet and exercise for weight gain associated with antidepressant use: a pilot study.
    Schwartz TL; Jindal S; Simionescu M; Nihalani N; Azhar N; Tirmazi S; Hussein J
    J Clin Psychopharmacol; 2004 Oct; 24(5):555-6. PubMed ID: 15349017
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.
    Zimmermann U; Kraus T; Himmerich H; Schuld A; Pollmächer T
    J Psychiatr Res; 2003; 37(3):193-220. PubMed ID: 12650740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.